INVENTIVA SA (IVA.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:IVA - FR0013233012 - Common Stock
IVA.PA Key Statistics, Chart & Performance
The current stock price of IVA.PA is 5.71 EUR. In the past month the price increased by 51.86%. In the past year, price increased by 168.71%.
IVA.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IVA.PA. When comparing the yearly performance of all stocks, IVA.PA is one of the better performing stocks in the market, outperforming 98.91% of all stocks.
IVA.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IVA.PA. IVA.PA may be in some trouble as it scores bad on both profitability and health.
IVA.PA Financial Highlights
Over the last trailing twelve months IVA.PA reported a non-GAAP Earnings per Share(EPS) of -3.62. The EPS decreased by -74.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -173.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IVA.PA Forecast & Estimates
14 analysts have analysed IVA.PA and the average price target is 13.57 EUR. This implies a price increase of 137.63% is expected in the next year compared to the current price of 5.71.
For the next year, analysts expect an EPS growth of 44.75% and a revenue growth 1.86% for IVA.PA
IVA.PA Ownership
IVA.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 64.82 | 42.92B | ||
| 1AE.DE | ARGENX SE | 64.86 | 42.73B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.67B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.03B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.02B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.92B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.91B | ||
| 6IV.DE | INVENTIVA SA | N/A | 967.31M | ||
| NANO.PA | NANOBIOTIX | N/A | 891.02M | ||
| PHIL.MI | PHILOGEN SPA | 19.12 | 637.43M | ||
| FYB.DE | FORMYCON AG | N/A | 424.96M | ||
| AYJ.DE | VALNEVA SE | N/A | 379.92M |
Related stock screener links
About IVA.PA
Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 84 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Info
INVENTIVA SA
50 rue de Dijon, Daix
Daix OCCITANIE FR
Employees: 116
Phone: 33380447500
INVENTIVA SA / IVA.PA FAQ
What does INVENTIVA SA do?
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 84 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
What is the current price of IVA stock?
The current stock price of IVA.PA is 5.71 EUR. The price increased by 8.14% in the last trading session.
Does INVENTIVA SA pay dividends?
IVA.PA does not pay a dividend.
How is the ChartMill rating for INVENTIVA SA?
IVA.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for IVA stock?
The Revenue of INVENTIVA SA (IVA.PA) is expected to grow by 1.86% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.